CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases

Molecular Pharmaceutics

Volumn 7, Issue 1, 2010, Pages 280-290

  Li, Shyh Dar ^a,b   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

CD44; Hyaluronan cisplatin microparticles; Intraperitoneal metastasis; Ovarian cancer

Indexed keywords

CARBOXYLIC ACID; CHLORIDE; CISPLATIN; HERMES ANTIGEN; HYALURONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL GROWTH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; FEMALE; FLOW CYTOMETRY; HIGH TEMPERATURE; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; INTERNALIZATION; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OVARY CANCER; PARTICLE SIZE; PERITONEAL CAVITY; PERITONEUM METASTASIS; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEIN TRANSPORT; TISSUE DISTRIBUTION; TUMOR MODEL;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYALURONIC ACID; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; PARTICLE SIZE; PERITONEAL NEOPLASMS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76249096802     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900242f     Document Type: Article

References (32)

1. Alberts, D. S.; Liu, P. Y.; Hannigan, E. V.; O'Toole, R.; Williams, S. D.; Young, J. A.; Franklin, E. W.; Clarke-Pearson, D. L.; Malviya, V. K.; DuBeshter, B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 1996, 335, 1950-1955.
2. Armstrong, D. K.; Bundy, B.; Wenzel, L.; Huang, H. Q.; Baergen, R.; Lele, S.; Copeland, L. J.; Walker, J. L.; Burger, R. A. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006, 354, 34-43.
3. de Bree, E.; Theodoropoulos, P. A.; Rosing, H.; Michalakis, J.; Romanos, J.; Beijnen, J. H.; Tsiftsis, D. D. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat. Rev. 2006, 32, 471-482.
4. Gadducci, A.; Carnino, F.; Chiara, S.; Brunetti, I.; Tanganelli, L.; Romanini, A.; Bruzzone, M.; Conte, P. F. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol. Oncol. 2000, 76, 157-162.
5. Markman, M.; Bundy, B. N.; Alberts, D. S.; Fowler, J. M.; Clark-Pearson, D. L.; Carson, L. F.; Wadler, S.; Sickel, J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 2001, 19, 1001-1007.
6. Polyzos, A.; Tsavaris, N.; Kosmas, C.; Giannikos, L.; Katsikas, M.; Kalahanis, N.; Karatzas, G.; Christodoulou, K.; Giannakopoulos, K.; Stamatiadis, D.; Katsilambros, N. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 1999, 56, 291-296.
7. Walker, J. L.; Armstrong, D. K.; Huang, H. Q.; Fowler, J.; Webster, K.; Burger, R. A.; Clarke-Pearson, D. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol. Oncol. 2006, 100, 27-32.
8. Yen, M. S.; Juang, C. M.; Lai, C. R.; Chao, G. C.; Ng, H. T.; Yuan, C. C. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int. J. Gynecol. Obstet. 2001, 72, 55-60.
9. Markman, M.; Rowinsky, E.; Hakes, T.; Reichman, B.; Jones, W.; Lewis, J. L., Jr.; Rubin, S.; Curtin, J.; Barakat, R.; Phillips, M.; Hurowitz, L.; Almadrones, L.; Hoskins, W. Phase I trial of intraperitoneal taxol: a gynecoloic oncology group study. J. Clin. Oncol. 1992, 10, 1485-1491.
10. Speyer, J. L.; Collins, J. M.; Dedrick, R. L.; Brennan, M. F.; Buckpitt, A. R.; Londer, H.; DeVita, V. T., Jr.; Myers, C. E. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980, 40, 567-572.
11. Zimm, S.; Cleary, S. M.; Lucas, W. E.; Weiss, R. J.; Markman, M.; Andrews, P. A.; Schiefer, M. A.; Kims, S.; Horton, C.; Howell, S. B. Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res. 1987, 47, 1712-1716.
12. Armstrong, D. K.; Fleming, G. F.; Markman, M.; Bailey, H. H. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 2006, 103, 391-396.
13. Hagiwara, A.; Takahashi, T.; Sawai, K.; Sakakura, C.; Tsujimoto, H.; Imanishi, T.; Ohgaki, M.; Yamazaki, J.; Muranishi, S.; Yamamoto, A.; Fujita, T. Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals. Br. J. Cancer 1996, 74, 1392-1396.
14. Kim, S.; Howell, S. B. Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy. Cancer Treat. Rep. 1987, 71, 705-711.
15. Natsugoe, S.; Tokuda, K.; Shimada, M.; Kumanohoso, T.; Baba, M.; Takao, S.; Tabata, M.; Nakamura, K.; Yoshizawa, H.; Aikou, T. Morphology of the designed biodegradable cisplatin microsphere. Anticancer Res. 1999, 19, 5163-5167.
16. Cannistra, S. A.; Kansas, G. S.; Niloff, J.; DeFranzo, B.; Kim, Y.; Ottensmeier, C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 1993, 53, 3830-3838.
17. Strobel, T.; Swanson, L.; Cannistra, S. A. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res. 1997, 57, 1228-1232.
18. Kayastha, S.; Freedman, A. N.; Piver, M. S.; Mukkamalla, J.; Romero-Guittierez, M.; Werness, B. A. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin. Cancer Res. 1999, 5, 1073-1076.
19. Rodriguez-Rodriguez, L.; Sancho-Torres, I.; Mesonero, C.; Gibbon, D. G.; Shih, W. J.; Zotalis, G. The CD44 receptor is a molecular predictor of survival in ovarian cancer. Med. Oncol. 2003, 20, 255-263.
20. Platt, V. M.; Szoka, F. C., Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharmaceutics 2008, 5, 474-486.
21. Cai, S.; Xie, Y.; Bagby, T. R.; Cohen, M. S.; Forrest, M. L. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J. Surg. Res. 2008, 147, 247-252.
22. Jeong, Y. I.; Kim, S. T.; Jin, S. G.; Ryu, H. H.; Jin, Y. H.; Jung, T. Y.; Kim, I. Y.; Jung, S. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J. Pharm. Sci. 2008, 97, 1268-1276.
23. Maeda, M.; Takasuka, N.; Suga, T.; Uehara, N.; Hoshi, A. Antitumor activity of a new series of platinum complexes: trans(±)-1,2- cyclohexanediammineplatinum(II) conjugated to acid polysaccharides. Anticancer Drugs 1993, 4, 167-171.
24. Selbi, W.; Day, A. J.; Rugg, M. S.; Fulop, C.; de la Motte, C. A.; Bowen, T.; Hascall, V. C.; Phillips, A. O. Overexpression of hyaluronan synthase 2 alters hyaluronan distribution and function in proximal tubular epithelial cells. J. Am. Soc. Nephrol. 2006, 17, 1553-1567.
25. Jandial, D. D.; Farshchi-Heydari, S.; Larson, C. A.; Elliot, G. I.; Wrasidlo, W. J.; Howell, S. B. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin. Cancer Res. 2009, 15, 553-560.
26. Kim, S.; Kim, D. J.; Geyer, M. A.; Howell, S. B. Multivesicular liposomes containing 1-β-D-arabinofuranosylcytosine for slow-release intrathecal therapy. Cancer Res. 1987, 47, 3935-3537.
27. Xie, Z.; Choong, P. F.; Poon, L. F.; Zhou, J.; Khng, J.; Jasinghe, V. J.; Palaniyandi, S.; Chen, C. S. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother. Pharmacol. 2008, 62, 949-957.
28. Yan, X.; Gemeinhart, R. A. Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles. J. Controlled Release 2005, 106, 198-208.
29. Nishiyama, N.; Okazaki, S.; Cabral, H.; Miyamoto, M.; Kato, Y.; Sugiyama, Y.; Nishio, K.; Matsumura, Y.; Kataoka, K. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 2003, 63, 8977-8983.
30. Haxton, K. J.; Burt, H. M. Hyperbranched polymers for controlled release of cisplatin. Dalton Trans. 2008, 5872-5875.
31. Tsai, M.; Lu, Z.; Wang, J.; Yeh, T. K.; Wientjes, M. G.; Au, J. L. Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel. Pharm. Res. 2007, 24, 1691-1701.
32. Zhou, B.; Weigel, J. A.; Fauss, L.; Weigel, P. H. Identification of the hyaluronan receptor for endocytosis (HARE). J. Biol. Chem. 2000, 275, 37733-37741.